1. Home
  2. ALXO vs LOAN Comparison

ALXO vs LOAN Comparison

Compare ALXO & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.08

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.35

Market Cap

51.9M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALXO
LOAN
Founded
2015
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
68.3M
51.9M
IPO Year
2020
1999

Fundamental Metrics

Financial Performance
Metric
ALXO
LOAN
Price
$2.08
$4.35
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$3.42
N/A
AVG Volume (30 Days)
998.4K
19.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
10.02%
EPS Growth
31.02
2.08
EPS
N/A
0.35
Revenue
N/A
$9,688,641.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4.47
P/E Ratio
N/A
$12.52
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$4.29
52 Week High
$2.66
$6.05

Technical Indicators

Market Signals
Indicator
ALXO
LOAN
Relative Strength Index (RSI) 49.66 31.16
Support Level $1.41 $4.29
Resistance Level $2.27 $4.59
Average True Range (ATR) 0.26 0.06
MACD -0.07 -0.00
Stochastic Oscillator 10.77 4.87

Price Performance

Historical Comparison
ALXO
LOAN

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: